By Enyichukwu Enemanna
The Africa Centres for Disease Control and Prevention on Tuesday said it requires at least $18 million in urgent funding to boost trials of experimental Ebola treatments in the Democratic Republic of Congo, warning that delays could jeopardize efforts to contain the outbreak.
The appeal comes as clinical trials evaluating potential therapies are due to begin this week in Bunia, capital of Ituri province in the East African country, where the first cases involving the Bundibugyo strain of Ebola were confirmed.
The trial programme is testing Gilead Sciences’ oral drug obeldesivir to prevent infection in people exposed to the virus, and remdesivir and Mapp Biopharmaceuticals’ antibody to reduce mortality among infected patients, the Africa CDC said.
The programme also includes accelerated development and manufacturing of next-generation Bundibugyo-specific vaccines, the agency added.
Funding for vaccine-related studies was largely in place, but therapeutic trials remained underfunded, Africa CDC said.
“We have the science. We now need the funding to use it. Clinical trials must start this week, and every day of delay costs lives we could save,” Africa CDC Director General, Dr. Jean Kaseya said.
The agency called on governments, development banks, philanthropic organizations and other partners to provide $16 million within days to continue the obeldesivir study and an additional $2 million to $3 million for contact tracing.
Africa is working with partners such as the World Health Organization, the International AIDS Vaccine Initiative and the Coalition for Epidemic Preparedness Innovations to assemble “one of the fastest scientific mobilizations ever mounted against a newly emerging Ebola strain,” it said.
